EVOEvotec SE
$1.57-61% 1Y
$1.57
$1.5352 weeks$4.15
Is the business good?
How good a business is EVO?
Evotec SE earns −12% on the capital it employs against a 9.0% cost of capital, so growth costs more than it returns.
−12%
Return on invested capital · cost of capital 9.0% · 21 points below what the capital costs: growth destroys value
- Operating margin
- −18%
Operating margin · Drug Manufacturers - Specialty & Generic median 11% · fiscal year to FY2024
- Share count, year on year
- +0.21%
Share count, year on year · flat: no meaningful dilution
- R&D as % of revenue
- 6.4%
R&D as % of revenue
| Year | Operating margin |
|---|---|
| FY2019 | 14% |
| FY2020 | 9.7% |
| FY2021 | 6.6% |
| FY2022 | 2.8% |
| FY2023 | −6.1% |
| FY2024 | −18% |
Details›
- Gross marginfiscal year to FY2024
- 14%
- Operating marginfiscal year to FY2024
- −18%
- Net marginfiscal year to FY2024
- −25%
- Free cash flow margin
- −12%
- R&D as % of revenue
- 6.4%
- Revenue, trailing twelve months
- $797M
- Free cash flow, trailing twelve months
- −$99M
- Net income, trailing twelve months
- −$196M
- Return on invested capitaloperating profit after tax ÷ debt + equity − cash
- −12%
Margins, capital and share counts from the statements as filed with the SEC; cash conversion is operating cash flow over operating profit after tax.
Drug Manufacturers, Specialty & Generic
Ranks #24 of 41 by RyuScore